Login to Your Account

Macugen Receives FDA's Broad Approval For All Wet AMD Types

By Aaron Lorenzo

Tuesday, December 21, 2004
The FDA authorized the first anti-angiogenic treatment for ophthalmology, Macugen, which received approval for the treatment of neovascular (wet) age-related macular degeneration.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription